Asian Research Journal of Current Science

4(1): 7-29, 2022; Article no.ARJOCS.716

Causes, Investigations, and Management in Patients with Pancreatitis

Omar Elsaka [a*], Moneer Ayman Noureldean [a], Mohamed Adel Gamil [a], Mostafa Tarek Ghazali [a], Ashraf Hamada Abd Al-Razik [a] and Dalia Hisham [a]

[a] Department of Gastroenterology, Mansoura University, Faculty of Medicine, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Review Article

Received 20 October 2021
Accepted 30 December 2021
Published 06 January 2022

ABSTRACT

Background: Acute pancreatitis is the most common cause of gastrointestinal-related hospitalization in the United States, and its incidence is on the rise in the US and around the world. The disease's severity ranges from the mild disease that requires conservative therapy to severe and complicated disease with a high rate of morbidity and mortality. This exercise examines the diagnosis and treatment of acute pancreatitis, emphasizing the importance of the interprofessional team in the treatment of this condition. The goals of this review article are to describe a patient presentation that is consistent with acute pancreatitis, summarise how to diagnose pancreatitis using the Revised Atlanta Classification, outline the treatment strategy for acute pancreatitis, and review the roles of interprofessional team members in the prevention and management of patients with acute pancreatitis. Acute pancreatitis is a dangerous condition with a mortality rate of 5 to 15%, depending on the cause, age of the patient, and comorbidity. Gallstone pancreatitis patients, on average, have a greater fatality rate than alcoholic pancreatitis patients.

Conclusion: This review article aims to describe a patient presentation consistent with acute pancreatitis, summarize how to use the Revised Atlanta Classification to diagnose pancreatitis, outline the treatment strategy for acute pancreatitis, and review the roles of interprofessional team members in both prevention of and management of patients with acute pancreatitis.

Keywords: Amylase; lipase; cystic fibrosis; acute; pancreatitis; fibrosis.

1. INTRODUCTION

Acute pancreatitis is a common gastrointestinal condition that is the top cause of hospitalization in the United States. The disease's severity ranges from the mild disease that requires conservative therapy to severe and complicated disease with a high rate of morbidity and mortality. The diagnosis of acute presentation is simple, but predicting the course and fate of the

**Corresponding author: Email: omarelsaka0808@gmail.com;*

disease is difficult. This is crucial in determining the level of care required [1].

2. ETIOLOGY

2.1 Common Causes

The majority of instances of acute pancreatitis are caused by long-term alcohol consumption and biliary stone disease, although there are various other causes. The origin is unknown in 10% to 30% of instances, while studies have suggested that biliary microlithiasis is responsible for up to 70% of idiopathic pancreatitis cases. Biliary tract disease (BTD) is a condition that affects the biliary Gallstones entering into the bile duct and temporarily lodging at the sphincter of Oddi is one of the most prevalent causes of acute pancreatitis in most developed nations (accounting for around 40% of cases). The risk of pancreatitis is inversely related to the size of the stone. Although this has not been established in people, it is assumed that acinar cell damage occurs as a result of increased pancreatic duct pressures generated by obstructive biliary stones at the ampulla of Vater. Most occurrences of idiopathic acute pancreatitis are caused by occult microlithiasis [2].

The consumption of alcohol is a leading cause of acute pancreatitis (accounting for at least 35 percent of cases). Ethanol causes the intracellular buildup of digestive enzymes, as well as their premature activation and release, at the cellular level. It increases the permeability of ductules at the ductal level, allowing enzymes to reach the parenchyma and cause pancreatic injury. Ethanol raises the protein content of pancreatic juice while lowering the levels of bicarbonate and trypsin inhibitors. This causes protein plugs to develop, which obstruct pancreatic outflow. Patients who have consumed alcohol regularly for 5 to 15 years are most likely to develop the condition. Acute aggravation of chronic pancreatitis is the most common reason for admission for alcoholics. However, pancreatitis can occur in patients who binge drink on weekends, and some case reports have reported a single substantial alcohol load triggering the first attack. Nonetheless, the alcoholic who consumes alcohol frequently is the rule rather than the exception when it comes to pancreatitis. There is currently no commonly recognized explanation for why some alcoholics are more likely to develop acute pancreatitis than other alcoholics who consume equivalent amounts of alcohol [3].

Endoscopic retrograde cholangiopancreatography: Endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is the third most prevalent kind of pancreatitis (accounting for approximately 4 percent of cases). While retrospective surveys suggest that the risk is only 1%, prospective investigations have found that the risk is at least 5%. If the endoscopist is inexperienced, the patient is suspected of having sphincter of Oddi dysfunction, or manometry is conducted on the sphincter of Oddi, the risk of post-ERCP acute pancreatitis is raised. In randomized investigations, aggressive pre-intervention intravenous (IV) hydration has been demonstrated to prevent post-ERCP pancreatitis. Rectal indomethacin, which has been shown to minimize the incidence of post-ERCP pancreatitis and is now universally approved at most institutions, has lately been used. The role of rectal indomethacin is still being debated in the literature. Abdominal trauma (around 1.5%) produces an increase in amylase and lipase levels in 17 percent of cases, as well as clinical pancreatitis in 5% of cases. Penetrating injuries (such as those caused by knives or bullets) are more likely to cause pancreatic harm than blunt abdominal trauma (eg, from steering wheels, horses, bicycles). A ductal injury can occur when a blunt impact to the abdomen or back crushes the gland across the spine [4].

Medications: Given the limited number of patients who acquire pancreatitis compared to the huge number of patients who receive potentially hazardous drugs, drug-induced pancreatitis is a relatively uncommon event (accounting for about 2% of cases) that is most likely due to an undiscovered propensity. Drug-induced pancreatitis, on the other hand, is usually minor. Azathioprine, Sulfonamides, Sulindac, Tetracycline, Valproic acid, Didanosine, Methyldopa, Estrogens, Furosemide, 6-Mercaptopurine, Pentamidine, 5-aminosalicylic acid compounds, Corticosteroids, Octreotide are all drugs that have been linked to acute pancreatitis. Chlorothiazide and hydrochlorothiazide, Methandrostenolone (methandienone), Metronidazole, Nitrofurantoin, Phenformin, Piroxicam, Procainamide, Colaspase, Chlorthalidone, Cimetidine, Cisplatin, Cytosine arabinoside, Diphenoxylate, and Ethacrynic acid are all drugs that have been linked to acute pancreatitis Furthermore, a variety of medicines have been linked to acute pancreatitis in isolated or sporadic cases [5].

2.2 Less Common Causes

Pancreatitis can be caused by a variety of infectious infections, especially in youngsters. Acute pancreatitis in this form is usually less severe than acute biliary or alcohol-induced pancreatitis. Mumps virus, coxsackievirus, cytomegalovirus (CMV), hepatitis virus, Epstein-Barr virus (EBV), echovirus, varicella-zoster virus (VZV), measles virus, and rubella virus are some of the viruses that cause these diseases. Mycoplasma pneumonia, Salmonella, Campylobacter, and Mycobacterium tuberculosis are examples of bacterial causes. Ascaris is a known cause of pancreatitis caused by worm migration in and out of the intestinal papillae all over the world. Pancreatitis has been linked to AIDS, but it could also be caused by opportunistic infections, neoplasms, lipodystrophy, or pharmacological treatments [6].

Hereditary pancreatitis is an 80 percent penetrance autosomal dominant gain-of-function condition caused by mutations in the cationic trypsinogen gene (PRSS1). Premature activation of trypsinogen to trypsin is caused by mutations in this gene. Furthermore, by generating ductal secretion anomalies, the CFTR mutation has a role in predisposing patients to acute pancreatitis. The phenotypic heterogeneity of patients with the CFTR mutation is not fully known at this time. Patients who are homozygous for the CFTR mutation are definitely at risk for pancreatic illness, but it's unclear which of the more than 800 variants poses the most danger. Furthermore, it is unknown what role CFTR heterozygotes have in pancreatic illness. A tendency to acute pancreatitis is likely caused by mutations in the SPINK1 protein, which inhibits the active binding site of trypsin, rendering it inactive. This most likely explains the predisposition to acute pancreatitis in these patients, rather than the cause. When a large number of mutant enzymes is activated intracellularly, they can overwhelm the first line of defense (the pancreatic secretory trypsin inhibitor) and overcome backup defenses (ie, proteolytic degradation by mesotrypsin, enzyme Y, and trypsin itself). The full zymogen activation cascade can then be triggered by activated mutant cationic trypsin. Acute pancreatitis can result from hypercalcemia for any reason. Hyperparathyroidism, high vitamin D dosages, familial hypocalciuric hypercalcemia, and complete parenteral feeding are some of the causes (TPN). The routine use of automated serum chemistries has enabled for earlier detection of hypercalcemia manifesting as pancreatitis and has lowered the frequency of pancreatitis [7].

Pancreas anomalies in development: The pancreas develops from two buds that emerge from the developing embryo's alimentary canal. Pancreatitis is often connected with two developmental abnormalities: pancreas divisum and annular pancreas. The failure of the dorsal and ventral pancreatic ducts to join during development is known as pancreas divisum. It is thought to be a variation of normal anatomy that affects about 5% of the population; in most cases, it may protect against gallstone pancreatitis. Stenotic minor papillae and an atretic duct of Santorini appear to be additional risk factors that, when combined, lead to the development of acute pancreatitis via an obstructive mechanism (although this is controversial). Annular pancreas is a rare congenital condition in which the second half of the duodenum is surrounded by a band of pancreatic tissue. Symptoms usually don't appear until later in life. This is an uncommon form of acute pancreatitis that is thought to be caused by an obstructive mechanism. Increased pancreatic ductal pressures caused by sphincter of Oddi dysfunction can lead to acute pancreatitis. The mechanism of pancreatitis generated by such dysfunction in people with normal sphincter pressures on manometry is, however, unknown [8].

Hypertriglyceridemia: Clinically severe pancreatitis does not usually develop until the blood triglyceride level reaches 1000 mg/dL. It's linked to hyperlipidemia of type I and type V. Although this is a debatable viewpoint, most experts believe that the link is caused by an underlying lipid metabolic disorder rather than pancreatitis-induced hyperlipidemia. This type of pancreatitis is more severe than that caused by alcohol or gallstones. Acute pancreatitis can be caused by a tumor obstructing the pancreatic ductal system, such as pancreatic ductal carcinoma, ampullary carcinoma, islet cell tumor, solid pseudotumor of the pancreas, sarcoma, lymphoma, cholangiocarcinoma, or metastatic tumor. When there is a tumor in the pancreas, the risks of pancreatitis are about 14%. Pancreatitis can also be caused by cystic neoplasms of the pancreas, such as intraductal papillary-mucinous neoplasm (IPMN), mucinous cystadenoma, or serous cystadenoma. Toxins: Acute pancreatitis can be caused by exposure to organophosphate insecticides. Scorpion and

snake bites can also induce acute pancreatitis; in Trinidad, the scorpion Tityus trinitatis sting is the most common cause. In both cases, hyperstimulation of pancreatic exocrine secretion appears to be the mechanism of action [9].

Surgical operations: Acute pancreatitis can develop following a variety of surgical procedures (eg, abdominal or cardiopulmonary bypass surgery, which may damage the gland by causing ischemia). Acute pancreatitis following surgery can be difficult to diagnose, and it has a higher complication risk than pancreatitis caused by other causes. The exact mechanism is unknown. Acute pancreatitis can be caused by vascular causes such as ischemia or vasculitis. Patients with polyarteritis nodosa and systemic lupus erythematosus are more likely to develop pancreatic ischemia as a result of vasculitis. Autoimmune pancreatitis is an extremely rare cause of acute pancreatitis that has only recently been identified (prevalence, 0.82 per 100,000 individuals). When it does induce acute pancreatitis, it mainly happens in young persons (under 40 years old) who already have other autoimmune illnesses. The cause is unknown, but it could be linked to immunoglobulin (Ig) G4 autoimmune illness [10].

3. PATHOPHYSIOLOGY

Pancreatitis pathogenesis includes both localized pancreatic damage and systemic inflammatory response. The premature activation of trypsinogen to trypsin within the acinar cell rather than in the duct lumen is the initiating event. This is thought to be caused by difficulties with calcium homeostasis and pH, as well as high ductal pressures (such as in duct obstruction). Because calcium transport is an ATP-dependent process, especially for sequestration in the smooth endoplasmic reticulum, many toxins that cause pancreatitis (including alcohol) are thought to cause ATP depletion, resulting in elevated intra-acinar calcium concentrations that stimulate early trypsinogen to trypsin activation, which activates enzymes like elastase and phospholipases. When these zymogens are activated early, they cause localized tissue damage and the production of Damage Associated Molecular Patterns (DAMPs). The release of DAMPs triggers neutrophil recruitment and the start of the inflammatory cascade. The systemic manifestations of acute pancreatitis are caused by this inflammatory cascade, which can lead to increased capillary permeability and endothelium damage, as well as microvascular thrombosis, which causes multiorgan dysfunction syndrome (MODS), the leading cause of morbidity and mortality in acute pancreatitis [11].

In recent years, it has been shown that certain people have a hereditary predisposition to pancreatitis. Recurrent acute pancreatitis and a progression to chronic pancreatitis are common in these patients. Associated genes play a role in trypsin activation, which is unsurprising. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which regulates bicarbonate secretion into pancreatic ductules, cationic trypsinogen gene (PRSS1) gain of function mutations, pancreatic secretory trypsin inhibitor (SPINK1) mutations, and trypsin degrading enzyme, chymotrypsin C (CTRC), all play a role in recurrent pan Furthermore, they are involved in a growing number of diseases ranging from acute to chronic pancreatitis [12].

4. HISTORY AND PHYSICAL PRESENTATION

The patient will usually complain of nausea and anorexia, as well as moderate to severe abdominal pain in the epigastrium. The discomfort can be different depending on whether the reason is a biliary obstruction or a metabolic/toxicologic issue. Biliary etiology is more commonly reported as a sharper pain that radiates through to the back and has a more abrupt onset, whereas metabolic and toxicologic causes, such as alcohol, are more typically described as a more indolent onset with dull and widespread discomfort. A detailed history of alcohol usage and medications should be obtained, keeping in mind that alcohol-related pancreatitis frequently requires more than five years of heavy drinking. A history of smoking is also a risk factor for acute pancreatitis. Because there are rare genetically connected cases of familial pancreatitis, family history should be explored, especially when more prevalent etiologies appear less likely. Elevated fever, tachycardia, and, in severe situations, hypotension are all signs to look for during a physical exam. Epigastric discomfort with probable guarding and rigidity, as well as reduced bowel sounds, are common findings on the abdominal exam. Grey-Turners sign emerges as ecchymosis at the flanks in severe cases of retroperitoneal bleeding, whereas Cullen's sign shows as periumbilical ecchymosis secondary to peritoneal hemorrhage [13].

5. COMPLICATIONS

Severe Acute Pancreatitis (SAP) is a biphasic disease with two phases: the "early" or "toxico-enzymatic" phase, which occurs in the first two weeks, and the "later" or "septic" phase, which occurs in the third to fourth week. However, not all cases of pancreatic necrosis are infectious, but all exhibit a toxic phase to varying degrees. This might range from quickly self-limiting conditions or situations that respond quickly to profuse rehydration to the rapid progression of severe SIRS and multi-organ failure (MOF) with sterile necrosis. We've learned that there isn't always a direct link between morphological and clinical severity of Severe Acute Pancreatitis (SAP), especially since the introduction of computed tomographic (CT) imaging. CT scans in the so-called fulminating types are typically not yet characterized by a frank necrotic component, because clear necrosis demarcation takes longer [14].

The discharge of "pancreatic broth" into the bloodstream causes impairment of cardiocirculatory, pulmonary, renal, and central nervous system functioning, and its reabsorption by the retroperitoneum and peritoneum causes pancreatic toxemia. The clinical status may change throughout the first two weeks, affecting one or more organ systems and occasionally superimposing or resembling early sepsis (sepsis-like syndrome). In these cases, radiologically guided fine-needle aspiration and bacteriological cultures of the specimens are required to confirm the presence of infected necrosis, as the presence of pathogenic bacteria is an absolute indication for surgery [15].

Biliary obstruction: The endoscopist has a better view of both the papilla and the bile sludge than the surgeon (surgically impalpable and radiologically difficult to demonstrate intraoperatively). Before pancreatic damage becomes "irreversible," all types of biliary Severe Acute Pancreatitis (SAP) require emergency endoscopic surgery (ES) within 36–48 hours (Neoptolemos 1994). With ES, it is feasible to improve a patient's clinical course and, in certain situations, avoid open surgery. Only in the rare circumstances where ES has failed is "open" treatment required. Although a recent Spanish multicenter study found a 29.4% mortality rate for early surgery against nil for delayed surgery for biliary Severe Acute Pancreatitis (SAP), the current consensus is that the timing of surgery is not a key determinant in the outcome of acute gallstone pancreatitis (Kg 1988) [16].

According to a review of the literature, patients who were operated on earlier had more severe disease than those who were operated on later, and choledochal stones could only be discovered in around 20% of those who were operated on earlier. The "criminal" stone has already gone in most cases of biliary Severe Acute Pancreatitis (SAP). Patients classified "biliary" by ultrasonographic and especially laboratory abnormalities should, if affected by the severe form, be treated with ES and then have laparoscopic cholecystectomy as soon as pancreatitis has subsided. Because the relapse risk during the usually recommended six-to-eight-week waiting time has been reported to range from 20 to 60%, we have adopted this strategy [17].

Multi-organ failure (MOF), failure to improve, and deterioration: Progression of clinical deterioration and severe SIRS despite appropriate support therapy is one of the most contentious grounds for early surgery. Because MOF owing to infected pancreatic necrosis is unusual in the early stages and often reveals itself from the third week onwards, this scenario is frequently linked with very widespread sterile necrosis. For the surgeon, there are no reliable clinical guidelines. Even the use of scoring systems, such as APACHE II, rather than plain clinical observation does not appear to have any effect. Many patients who were earlier certain to die within 36–48 hours are now surviving the early toxic phase thanks to advanced resuscitation procedures, reducing the severity of the condition. Those who "do badly" today, on the other hand, are the terminally ill. We feel that in these severely ill and fast deteriorating individuals, a surgical attempt, however improbable, to remove the toxemia-causing endo-retroperitoneal "enzymatic broth" is justified. Unfortunately, scientific evidence strongly supporting this approach is difficult to come by, partly because the planning of prospective, randomized, controlled trials is ethically dubious and statistically flawed due to the small number of patients that can be recruited in a reasonable amount of time [18].

There was no statistically significant difference in mortality rates between operated and non-operated patients in one non-randomized study (46 vs. 31 percent), but given the small number of patients and the fact that the surgical timing

was not exactly early (20.5 days after onset of disease), no conclusive indications can be established. Neither the early nor late deployment of pancreatic resection procedures utilized in a Finnish study changed the prognosis in individuals with MOF. We used the treatment known as retro-endoperitoneal draining and postoperative lavage to treat 59 patients with MOF who were refractory to rigorous medical therapy within the first two weeks of the disease. We had a 30.5 percent (18/59 patients) mortality rate, which appears reasonable given the severity of the condition (mean Ranson score 4.9 and mean APACHE II score 19.1). In conclusion, early surgery will not benefit all patients with MOF in the course of Severe Acute Pancreatitis (SAP). Peritoneal lavage may have a favorable effect in these circumstances, but it is not directed towards the retroperitoneum, which is the main site of the inflammatory-toxic process. Despite initial enthusiasm for this method, no good results have been achieved [19].

Early infected necrosis: Only 15% of infected Severe Acute Pancreatitis (SAP) patients treated in our department showed indications of infection during the first two weeks of the sickness, corroborating what we've already indicated regarding the complication's normal onset time. The therapeutic principles are the same as in later infections, albeit it is crucial to remember that the presence and activity of toxemia may make the diagnosis of this complication more challenging. In most cases, a delay in diagnosis can prove fatal in these patients [20].

Hemorrhage and peritonitis: In those fortunately uncommon situations of bleeding, a decision to operate or, in some circumstances, for angiographic embolization, appears indisputable, although the clinical picture of peritonitis (on an enzymatic basis) must be carefully reviewed before deciding on surgical treatment. After 24–48 hours of rigorous medical therapy, the latter mentioned individuals often improve or even recover from the acute period. Peritonitis in the course of Severe Acute Pancreatitis (SAP) isn't always a sign that you need a laparotomy. A diagnostic laparotomy may be necessary to rule out alternative causes of the "acute abdomen." Exploratory laparotomy does not appear to worsen pancreatitis, but it does have the potential to "convert" sterile necrosis to infected pancreatic necrosis. Extensive sterile necrosis: Most writers consider sterile necrosis that covers more than half of the pancreatic volume to be a surgical indication [21].

We concur with others that the amount of necrosis, which can be accurately quantified using CT results and C-reactive protein levels, is a strong predictor of infection risk. However, because there is no clear relationship between morphological and clinical severity, the amount of necrosis cannot be utilized as a foundation for surgical indication, particularly in the early stages. In contrast to Warshaw's team's findings, which suggest that early sterile necrosis debridement is advantageous, others indicate that medical therapy was successful in a prospective trial of eleven patients with significant sterile necrosis, even in cases with concomitant pulmonary and renal failure. Thus, even when accompanied by organ failure, pancreatic necrosis is not an unequivocal justification for surgery. Identification of predictive prognostic factors is important to be able to better tarfon therapy approaches to particular disease severity scores. In this sense, shock appears to be the most negative prognostic factor [21].

Rupture of the Wirsung's duct: Rupture of the Wirsung's duct is considered by some to be an indication for a resective operation because drainage would result in the establishment of an external pancreatic fistula. With endoscopic retrograde cholangiopancreatography (FRCP), it is now possible to show that the main duct is much more frequently implicated in the acute phase of Severe Acute Pancreatitis (SAP) than previously thought. In our opinion, it seems fairer to wait for one to two months after acute pancreatitis has passed before draining the pseudocyst (the "natural" conclusion of Wirsung rupture) rather than treating the lesion while it is still in the acute phase of Severe Acute Pancreatitis (SAP). This appears to be a better option than resection, which has high morbidity and fatality rates [22].

6. PREVENTION

When the etiology of pancreatitis is identified, the best way to prevent future episodes is to stop the etiologic agent from producing them. Patients with proven gallstone pancreatitis, as well as those with idiopathic recurrent pancreatitis, are at a higher risk. A cholecystectomy is necessary. A dedicated individual (e.g., physician, psychologist, addiction counselor) who can help the patient overcome the addiction to alcohol is essential in patients who abuse alcohol. When a rare cause of pancreatitis is discovered, the

strategy for prevention is tailored to the cause [23].

7. EPIDEMIOLOGY

In general, the incidence of acute pancreatitis is increasing in the United States and around the world. It's impossible to say if this tendency is due to an increase in incidence or merely increased detection. Increased hypertriglyceridemia and metabolic syndrome are thought to be contributing to the rise in incidence, with many findings indicating an increase in acute pancreatitis as a result of hypertriglyceridemia. Despite the growing incidence, mortality in the United States has reduced, with most recent studies reporting a fatality rate of around 2%. Acute pancreatitis is more common in people in their fifth and sixth decades, but mortality rises with age. The incidence of acute pancreatitis is thought to vary by geographic region and socioeconomic status and is likely linked to differences in alcohol consumption and the presence of biliary calculi, the two major causes of acute pancreatitis. In the United States, the population incidence has recently been estimated to be 600 to 700 per 100,000 persons, with 200,000 to 250,000 acute pancreatitis discharges per year [24].

8. INVESTIGATIONS

Laboratory tests are obtained to support the clinical impression of acute pancreatitis once a working diagnosis of acute pancreatitis is made. Laboratory testing is useful in establishing the cause and looking for consequences in addition to verifying the diagnosis. Although diagnostic imaging is not required in most cases of pancreatitis, visualizing inflammatory abnormalities within the pancreas can help confirm the diagnosis. When in doubt about a diagnosis, when severe pancreatitis is present, or when a specialized imaging study might provide precise information needed to solve a clinical question, get imaging testing. Image-guided aspiration can help distinguish infectious necrosis from sterile necrosis and remove the fluid accumulation. Even if effective treatments for certain hereditary diseases are lacking, genetic testing for mutations related to acute pancreatitis may be considered [25].

9. LABORATORY STUDIES

Amylase and lipase: Amylase and lipase levels in the blood are usually high in those who have acute pancreatitis. These rises, on the other hand, could just suggest pancreastasis. Amylase or lipase levels that are at least three times higher than the reference range are generally regarded as indicative of acute pancreatitis in research investigations. Although serum amylase readings are common, they are not specific for pancreatitis. It is preferable to assess the amylase P level, which is more specific to pancreatic disease. Patients with small intestine obstruction, mesenteric ischemia, tubo-ovarian illness, renal insufficiency, or macroamylasemia may have elevated levels. Elevations can occasionally indicate parotitis. Amylase has a short half-life in the blood, therefore increases usually revert to normal within a few days. Lipase has a somewhat longer half-life, and anomalies in this enzyme may help to confirm the diagnosis if there is a time delay between the onset of pain and the time the patient seeks medical help. Lipase elevations are more specific to the pancreas than amylase elevations. Lipase levels stay elevated for 12 days. Lipase levels may be high in patients with chronic pancreatitis (typically induced by alcohol misuse), even if serum amylase levels are normal. The presence of serum amylase or lipase does not indicate whether the disease is mild, moderate, or severe, and serial monitoring of levels during hospitalization does not provide information about the prognosis [26].

Enzymes linked to the liver: To look for signs of gallstone pancreatitis, check your alkaline phosphatase, total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels. A level of ALT of more than 150 U/L indicates gallstone pancreatitis and a more severe disease course. Electrolytes in the blood, BUN, creatinine, glucose, cholesterol, and triglycerides in the blood: Obtain blood urea nitrogen (BUN), creatinine, and electrolyte values; a significant disturbance in the electrolyte balance is frequently discovered as a result of the third spacing of fluids. Because of B-cell damage in the pancreas, blood glucose levels may be raised.Measure calcium, cholesterol, and triglyceride levels to look for a pancreatitis etiology (e.g., hypercalcemia or hyperlipidemia) or pancreatitis sequelae (eg, hypocalcemia resulting from saponification of fats in the retroperitoneum). However, during an episode of acute pancreatitis, baseline serum triglyceride levels can be artificially reduced [27].

Complete blood count (CBC) and hematocrit: A complete blood count (CBC) reveals leukocytosis (WBC count greater than 12,000/L) with a shift in the differential toward segmented polymorphonuclear (PMN) cells. Inflammation or infection can cause leukocytosis. Hemoconcentration at admission (a hematocrit value of more than 47% at admission) has been postulated as a sensitive indicator of more severe illness. However, it was later discovered that this was only useful as a negative predictor, meaning that a lack of hemoconcentration effectively rules out serious illness. Obtain type and cross-match if blood transfusion is required, such as in cases of hemorrhagic pancreatitis. C-reactive protein (CRP): 24-48 hours following presentation, a C-reactive protein (CRP) result can be acquired to provide some indication of prognosis. Increased levels have been linked to an increased risk of organ failure. A CRP level in the double digits (i.e. 10 mg/dL) suggests serious pancreatitis. CRP is an acute-phase reactant that is not specific for pancreatitis [28].

If a patient is dyspneic, perform an arterial blood gas analysis. It must be determined whether the tachypnea is caused by acute respiratory distress syndrome (ARDS) or diaphragmatic irritation. The levels of lactic dehydrogenase (LDH), BUN, and bicarbonate should be tested at admission and 48 hours to assist determine the Ranson criterion for survival. Immunoglobulin G4 (IgG4) levels might be examined to see if you have autoimmune pancreatitis, especially if you have recurring acute pancreatitis with no evident cause. However, because IgG4 levels can be high in as many as 10% of individuals with acute pancreatitis who do not have autoimmune pancreatitis, this test is not specific. Although trypsin and its precursor trypsinogen-2 have been investigated as potential indicators for acute pancreatitis (particularly post-ERCP pancreatitis), they are not routinely used. When trypsinogen is broken to generate trypsin, a peptide called trypsinogen activation peptide (TAP) is formed, which may be tested commercially in the urine to diagnose acute pancreatitis and help define its severity. Polymorphisms in the chemokine monocyte chemotactic protein 1 (MCP-1) gene may also indicate severity, albeit they are not currently used in treatment trials. This is the first gene to be discovered that is solely responsible for predicting disease severity [29].

10. ABDOMINAL RADIOGRAPHY

In acute pancreatitis, abdominal radiographs have a limited role. With the patient in the upright posture, kidneys-ureters-bladder (KUB) radiography is used to identify open air in the abdomen, which indicates a perforated viscus, as in a penetrating, perforated duodenal ulcer. The inflammatory process can damage peripancreatic tissues, causing a colon cut-off sign, a sentinel loop, or an ileus in some situations. Calcifications inside or around the pancreas could suggest chronic pancreatitis (Fig. 1) [29].



Fig. 1 Chronic pancreatitis on plain abdominal radiographs: Abdominal radiographs (a, b) of two alcoholic patients show multiple coarse calcifications in the topography of the pancreas (arrows) [29]

11. ULTRASONOGRAPHY

11.1 Abdominal Ultrasonography

The most useful initial test for establishing the origin of pancreatitis is abdominal ultrasonography, which is also the tool of choice for discovering gallstones. Sensitivity is lowered to 70% to 80% in the presence of acute pancreatitis. Furthermore, choledocholithiasis is difficult to diagnose. Although ultrasonography can be used as a screening test, if there are underlying gas shadows due to intestinal distention, it may not be specific. Ultrasonography is not capable of determining the severity of an illness (Figs. 2, 3) [30].



Fig. 2. Chronic pancreatitis on US: A 45-year-old male with epigastric pain and history of alcohol abuse. Transverse (a) and sagittal (b) images of the pancreas show multiple hyperechoic non-shadowing foci in the pancreatic parenchyma (arrows) associated with mild dilatation of the pancreatic duct. Finding is better appreciated in sagittal view (arrowhead) [30]



Fig. 3. Chronic pancreatitis on US: A 19-year-old male patient with repetitive attacks of pancreatitis. Transverse images of the pancreas (a, b) reveal a marked, smooth, dilated, tortuous pancreatic duct in the body and tail of the pancreas with abrupt cut off in the neck (arrows). Note the presence of a small pseudocyst around the head of the pancreas (arrowhead). MRCP performed in this patient showed a pancreatic divisum with stenosis of the proximal dorsal duct [30]

11.2 Endoscopic Ultrasonography

Endoscopic ultrasonography (EUS) is an endoscopic treatment that involves inserting a high-frequency ultrasound transducer into the GI system to see the pancreas and biliary tract. Because the high-frequency transducer may be inserted immediately close to the pancreas, this study allows for a more detailed image than transcutaneous ultrasonography. Its main purpose in the diagnosis of acute pancreatitis is to detect microlithiasis and periampullary lesions that are difficult to detect with other modalities. This method should not be utilized to diagnose chronic pancreatitis until several months following an acute pancreatitis event. A secretin-stimulated EUS investigation in specialized centers with highly trained medical staff may indicate resistance to ductal outflow at the level of the papilla, as evidenced by pancreatic duct dilatation to a higher extent and for a longer duration than in a healthy population. This can help evaluate patients with recurrent idiopathic pancreatitis [31].

11.3 Computed Tomography Scanning

Patients with mild pancreatitis should not undergo abdominal computed tomography (CT) scanning unless a pancreatic tumor is detected (usually in elderly patients). It is always recommended in patients with severe acute pancreatitis and is the preferred imaging technique for determining complications. Scans are rarely needed within the first 72 hours of symptom onset unless the diagnosis is unclear, as inflammatory alterations are frequently not visible radiographically until then. CT scans of the abdomen also provide prognostic information based on the grading scheme produced by Balthazar and colleagues: Grade A: Normal pancreas; Grade B: Focal or diffuse gland enlargement; Grade C: Intrinsic gland abnormality identified by haziness on the scan; Grade D: Intrinsic gland abnormality recognized by haziness on the scan; Grade E: Intrinsic gland abnormality recognized by haziness on the scan; Grade F: Intrinsic gland abnormality recognized by haziness Grade D indicates a single ill-defined collection or phlegmon, while Grade E indicates two or more ill-defined collections or the presence of gas in or around the pancreas (Figs. 4, 5, 6) [31].

In grades A and B, the chances of infection and death are almost zero, but they rapidly grow in grades C through E. A patient with grade E pancreatitis has a 50% likelihood of contracting an infection and a 15% chance of dying. The presence and degree of pancreatic necrosis are determined by dynamic spiral CT scanning. A study of the upper abdomen is performed twice, before and after the administration of an intravenous (IV) bolus of iodine contrast agent, after the administration of an oral agent to characterize intestinal structures. Density numbers for a healthy pancreas range from 30-40 Hounsfield units on an unenhanced study to 100-150 Hounsfield units on an improved examination. When pancreatic necrosis is observed, unenhanced parenchyma in focal or diffuse areas on the second scan indicates pancreatic necrosis. For research purposes, pancreatic necrosis is defined as a loss of enhancement in at least 30% of the pancreatic parenchyma [32].



Fig. 4. Chronic pancreatitis on CT: A 57-year-old male with alcohol abuse. CECT axial images (a, b) show a dilated pancreatic duct, multiple calcifications (arrows) throughout the pancreas, and parenchymal atrophy [31]



Fig. 5. Chronic pancreatitis on CT: A 73-year-old with history of alcohol abuse. CECT axial images (a, b) reveal a prominent dilated main pancreatic duct (arrows), marked parenchymal atrophy, and multiple calcifications in the pancreas [31]



Fig. 6. Chronic pancreatitis on CT: A 37-year-old male with history of cystic fibrosis.Non-contrast CT axial images (a, b) reveal multiple, small pancreatic calcifications and parenchyma atrophy with diffuse fatty infiltration (arrows) of the pancratic parenchyma [31]

11.4 Magnetic Resonance Imaging

Early and late MRI results for hereditary pancreatitis can be distinguished. Low-signal-intensity pancreas on T1-weighted fat-suppressed imaging, decreased and delayed enhancement after IV contrast injection, and dilated side branches are all possible early observations. Late observations may include parenchymal atrophy or enlargement, pseudocyst formation, pancreatic duct dilatation and beading, and intraductal calcifications, resulting in a 'chain of lakes' look (Fig. 7) [32].

11.5 Magnetic Resonance Cholangiopancreatography

In the setting of pancreatitis, magnetic resonance cholangiopancreatography (MRCP) is becoming more often used in the identification of suspected biliary and pancreatic duct obstruction. The biliary and pancreatic ducts can be visualized noninvasively using heavily T2-weighted images. Although MRCP is not as sensitive as endoscopic retrograde cholangiopancreatography (ERCP), it is safer, non-invasive, and quick, and it produces images that can help clinicians make better decisions. If choledocholithiasis is suspected, MRCP should be utilized instead of ERCP since ERCP may aggravate pancreatitis (Fig. 8) [33].

11.6 Endoscopic Retrograde Cholangiopancreatography

Endoscopic retrograde cholangiopancreatography (ERCP) is an endoscopic procedure that is performed to assess the biliary and pancreatic ductal systems in a subgroup of individuals who have acute

pancreatitis. However, in patients with acute pancreatitis, ERCP should be utilized with extreme caution and should never be employed as a first-line diagnostic technique. This technique should only be used in the following circumstances: The patient has severe acute pancreatitis that is thought to be attributable to choledocholithiasis, as evidenced by additional radiographic investigations. Despite maximal supportive care, the patient has biliary pancreatitis and is experiencing severe jaundice and clinical deterioration. When paired with sphincterotomy and stone removal, ERCP has the potential to reduce hospital stay, complication rate, and mortality. In the case of biliary pancreatitis, ERCP with sphincterotomy is recommended within the first 72 hours if a dilated obstructed common bile duct is diagnosed based on CT scanning or any other imaging modality and a high plasma bilirubin level (>5 mg/dL). After the symptoms of biliary pancreatitis have eased, a cholecystectomy should be performed (Fig. 9) [34]



Fig. 7. Hereditary pancreatitis MRI [32]



Fig. 8. Chronic Pancreatitis via MRCP [33]



Fig. 9. ERCP (A) and magnetic resonance cholangiopancreatography (B) showed complete interruption (arrows) of the pancreatic duct in the body of the pancreas [34]

11.7 Image-Guided Aspiration and Drainage

In patients with severe necrotizing pancreatitis, CT-guided needle aspiration is utilized to distinguish infectious necrosis from sterile necrosis. Following the first week of severe pancreatitis, the needle is inserted into a low attenuation area in or around the pancreas of a patient with fever, tachycardia, or other symptoms of a systemic inflammatory response syndrome. If clinically required, the operation might be repeated weekly. Within an hour, the specimen should be transferred to the laboratory and interpreted. Gram stain, culture, and sensitivity should all be checked on every specimen. Surgical debridement of the infected necrosis is usually recommended if the Gram stain reveals bacteria or fungi. If the patient is unable to withstand surgery, CT-guided catheter drainage may be more effective. Endoscopic ultrasonography (EUS)-guided needle aspiration, like CT-guided needle aspiration, is frequently used to distinguish infected necrosis from sterile necrosis. EUS can also be utilized to guide the drainage of pancreatic and peripancreatic fluid collections that have developed after an acute pancreatitis episode has become complicated. After the pseudocyst has had time to form, these operations should be carried out [34].

12. GENETIC TESTING

With the advent of molecular medicine, several genetic disorders associated with pancreatitis have been discovered. Rather than subjecting the entire group to the hazards of endoscopic sphincterotomy or stent implantation for presumptive diagnosis of sphincter of Oddi failure, it is occasionally feasible to begin testing for these mutations in individuals with otherwise idiopathic pancreatitis. As more is discovered about molecular processes and therapy, clinical trials may potentially give logical new medicines to these individuals. Of course, before undergoing any form of genetic testing, all individuals should seek competent genetic counseling that addresses social, familial, insurance, and financial concerns. In reality, it is the author's policy not to do any genetic testing unless a trained genetic counselor has first educated the patient. A mutation of cationic trypsinogen has been linked to hereditary pancreatitis (PRSS1). So far, at least four mutations have been discovered. The protein appears to be resistant to second-line proteolytic defense mechanisms as a result of these alterations. By the time they reach their mid-teens, patients with PRSS1 mutations have experienced their first bout of pancreatitis. A substantial family history of pancreatic illness is most common (eg, acute or chronic pancreatitis, pancreatic malignancy). It should be mentioned that pancreatitis caused by PRSS1 is extremely uncommon [35].

Atypical mutations in the CFTR gene, which is inherited in an autosomal recessive fashion, are found in certain people with idiopathic pancreatitis. This is an exciting step forward in

our knowledge of the cystic fibrosis spectrum, in which phenotypic expression is determined by the degree to which the mutation alters the CFTR enzyme's function. Minor changes in the pancreas that do not alter pulmonary function may influence chloride transport enough to predispose people to recurrent idiopathic pancreatitis. Patients with mutations in the SPINK1 gene are more likely to develop acute pancreatitis. The SPINK1 protein binds to trypsin's active binding region, making it inert. In the United States, however, about 1 in 100 people is at least heterozygous for SPINK1. It is inherited in an autosomal recessive gene pattern. Therefore, although mutations of the SPINK1 gene are not usually enough to cause pancreatitis, they are likely to be a cofactor responsible for pancreatitis in some individuals [35].

13. HISTOLOGIC FINDINGS

The infinite spectrum of pancreatitis severity is commonly categorized into moderate and severe categories for practical purposes as follows: Mild pancreatitis: The pancreas displays interstitial edema and an inflammatory infiltration without bleeding or necrosis, and organ dysfunction is usually modest. Extensive inflammation and necrosis of the pancreatic parenchyma are observed in severe pancreatitis, which is frequently linked with severe gland dysfunction and multiorgan system failure. Necrosis mostly affects peripancreatic fatty tissue during surgery, whereas the gland is usually unaffected; as a result, the extent of pancreatic necrosis is frequently overstated. Arterial thrombosis can cause panlobular infarction, in which the gland becomes a hemorrhagic, necrotic, and gangrenous mass. Fat necrosis has a different natural history depending on its location and extent; tiny portions (less than 1 cm) may resolve completely, but larger sections (more than 5 cm) may liquefy within a fibrotic capsule [35].

14. STAGING

The Ranson, Acute Physiology and Chronic Health Evaluation (APACHE) II, Glasgow, and Imrie scoring systems have all been used to predict the severity and outcome of acute pancreatitis. Each has its own set of benefits and drawbacks, and none of them is now accepted as a criteria standard. The Atlanta classification of acute pancreatitis has been used to distinguish between severe and moderate cases of acute pancreatitis for research reasons. Patients with severe acute pancreatitis are identified using this categorization if they exhibit the following symptoms: Evidence of organ failure (e.g., systolic blood pressure less than 90 mm Hg, arterial partial pressure of oxygen [Pa O2] 60 mm Hg or lower, serum creatinine level 2 mg/dL or higher, gastrointestinal bleeding of 500 mL or more in 24 hours).Local consequences (such as necrosis, abscess, or pseudocyst), as well as a Ranson score of 3 or higher or an APACHE score of 8 or higher [36].

Ranson criteria: Ranson developed a grading system based on several distinct criteria for the severity of acute pancreatitis that is still extensively used today. The following are some of the admissions criteria: Patient over 55 years old with a WBC count of 16,000/L, a blood glucose level of 200 mg/dL, a serum LDH level of 350 IU/L, and an AST level of 250 IU/L. The following are some of the criteria that emerge over the first 48 hours: A drop in hematocrit of more than 10%, a rise in BUN of more than 8 mg/dL, a drop in serum calcium of less than 8 mg/dL, a Pa O2 of less than 60 mm Hg, a base deficit of more than 4 mEq/L, and estimated fluid sequestration of more than 6 L [36].

Each of the aforementioned criteria contributes one point to the overall score. A Ranson score of 0-2 indicates that the patient is unlikely to die, and he or she is admitted to the regular ward for medical treatment and assistance. A Ranson score of 3-5 indicates a 10% to 20% chance of death, and the patient should be admitted to the intensive care unit (ICU). After 48 hours, a Ranson score of more than 5 has a mortality rate of more than 50% and is linked to increased systemic problems. Despite being the most well-known grading system, the Ranson criteria have significant flaws. To begin, 11 criteria are employed, some of which are reviewed on the first day and others on the second. The Ranson score is only valid 48 hours after the commencement of the disease and not at any other time during the illness. Second, the threshold for an abnormal value depends on whether the pancreatitis is caused by alcohol or gallstones. Finally, the sensitivity is only 73% and the specificity is 77% for predicting mortality [37].

BUN: An increase in severe acute pancreatitis and/or death has been linked to a high BUN level at admission. This is a good match for the APACHE II score. Hemoconcentration, a proxy marker for intravascular depletion, is assumed to be the cause of the spike in BUN. In acute

pancreatitis, intravascular depletion is regarded to be a crucial modulator of the inflammatory response [37].

APACHE II: The APACHE score has the advantage of being able to assess the patient at any moment during the illness; nevertheless, it is extremely difficult to utilize in ordinary clinical practice. There have been attempts to make this evaluation more user-friendly (e.g., with APACHE II, the Simplified Acute Physiology Score [SAPS], and the Imrie score), but it remains difficult. The specificity is 84 percent, and the sensitivity is 77%. The APACHE II Scoring System calculator can be found here [37].

The hematocrit number is the most extensively used biological marker for determining the severity of acute pancreatitis. The presence of a hematocrit value of more than 47% at admission has been reported as a sensitive predictor of pancreatic necrosis. However, a later study found that admission hematocrit is only useful as a negative predictor of necrosis in patients who do not have hemoconcentration. At 36-48 hours, CRP, a nonspecific acute-phase reactant generated by the liver in response to interleukin (IL)–6, can be used as a marker. Severe acute pancreatitis is defined by a CRP level of greater than 6 at 24 hours and greater than 7 at 48 hours. This test has a sensitivity of 73 percent and a specificity of 71 percent. In the first few hours of pancreatitis, IL-6 levels rise, promoting the release of CRP. Early research on IL-6 as a biological marker has yielded promising results, suggesting that it could be a reliable indicator of pancreatitis severity. This result has yet to be confirmed, and IL-6 is not currently commercially accessible for usage in this situation. Several other blood tests have shown promise in predicting acute pancreatitis severity. TAP (trypsinogen activation peptide), polymorphonuclear elastase, and phospholipase A2 are among them. They are not commonly used in clinical practice, and they are more expensive than commonly used assays, similar to IL-6. Some are only marginally superior to CRP [38].

Polymorphisms in the chemokine monocyte chemotactic protein 1 (MCP-1) gene may play a role in predisposing patients to severe acute pancreatitis, however, this marker is currently being studied and is not used clinically [38].

15. GRADING OF SEVERITY OF ACUTE PANCREATITIS

The pancreatitis severity scale was changed in the new Atlanta classification to facilitate patient categorization at the time of presentation. The initial classification divided patients into two groups: those with severe pancreatitis and those with moderate pancreatitis, based on the presence or absence of organ failure. Emerging studies, on the other hand, suggested that a sizable subset of patients with local problems had significant morbidity but low death. As a result, a third category, moderately severe acute pancreatitis was introduced to the revised categorization to describe this patient group. Patients with mild pancreatitis, who are frequently released within the first week and have a low death rate, do not experience organ failure or local consequences. Local consequences are uncommon in these patients, and imaging may be beneficial primarily in determining the origin of pancreatitis (eg, ultrasonography [US] or MR cholangiopancreatography for choledocholithiasis) [38].

Patients with moderately severe acute pancreatitis have temporary organ failure lasting fewer than 48 hours, as well as local or systemic consequences. Acute kidney damage in the setting of chronic renal insufficiency is an example of a systemic consequence aggravated by pancreatitis. A variety of pancreatic and peripancreatic collections are among the local consequences. Patients with unremitting or recurrent pain, a subsequent peak in pancreatic enzyme levels, deteriorating organ failure, or sepsis are clinically suspected of having such collections in the second week (late phase of pancreatitis). These symptoms should trigger imaging procedures such as contrast-enhanced CT, contrast-enhanced MR imaging, or unenhanced MR imaging (in order of preference) [38].

Organ failure that lasts longer than 48 hours is a sign of severe illness. Because organ failure is so important in identifying the severity of the disease, a precise definition is critical for clinical management of acute pancreatitis. The updated Atlanta classification recommends the modified Marshall scoring system as the primary way for identifying organ failure. A score of 2 or greater for any system indicates organ failure, according to the modified Marshall scoring system, which

Table 1 Modified marshall scoring system [38]

Organ system	Score 0	Score 1	Score 2	Score 3	Score 4
Respiratory*	>400	301-400	201-300	101-200	≤100
Renal: serum creatinine (mg/dL)	≤1.4	1.5-1.8	1.9-3.5	3.6-4.9	≥5
Cardiovascular: systolic blood pressure (mm Hg)	>90	<90, responding to fluid resusci-tation	<90, not responding to fluid resus- citation	<90 with pH <7.3	<90 with pH <7.2

*Note: A score of 2 or higher indicates organ failure, with transient failure lasting less than 48 hours and persistent failure lasting more than 48 hours.(*Partial pressure of oxygen/fraction of inspired oxygen, or PaO2/FIO2)*

integrates data from the respiratory, cardiovascular, and renal systems (Table 1) [38].

16. DIFFERENTIAL DIAGNOSIS

The differentials for acute pancreatitis include the entire differential for abdominal pain, which can be narrowed significantly with a thorough history and physical examination, as detailed above. Differential diagnoses can include, but are not limited to: Peptic ulcer disease, Cholangitis, Cholecystitis, Bowel perforation, Bowel obstruction, Mesenteric ischemia, Acute hepatitis, Diabetic ketoacidosis, Basilar pneumonia, Myocardial infarction, Renal colic, and aortic dissection are some of the conditions that can cause aortic dissection. Because of its high specificity, and increased lipase level three times the upper limit of normal will allow for the diagnosis of pancreatitis as the cause of abdominal discomfort in many of these instances. When mesenteric ischemia is high in the differential, an abdominal ultrasound can help differentiate cholecystitis, but a CT angiography can be employed when mesenteric ischemia is high on the differential. In high-risk individuals, the cardiac source of pain should be ruled out at the same time, as epigastric discomfort might present atypically. Progressing aortic dissection should be considered due to its particularly urgent nature, though the pain is often more severe and tearing than for those with acute pancreatitis [39].

17. MANAGEMENT

The medical treatment of mild acute pancreatitis is rather simple. The patient is kept NPO (nothing by mouth) and is given intravenous (IV) fluids. Analgesics are used to alleviate discomfort. Antibiotics are usually not recommended. Cholecystectomy should be performed during the same hospital admission if ultrasonograms reveal gallstones and the cause of pancreatitis is suspected to be biliary. As the patient's anorexia and pain subside, enteral feeding should be administered. Patients do not always need to begin their dietary progression with a clear liquid diet and can begin with a low-fat diet. When compared to parenteral nutrition, systematic reviews and meta-analyses have demonstrated that enteral nutrition may minimize mortality and infection complications. Although the optimal time for starting enteral feeding is unknown, given within 48 hours appears to be safe and well-tolerated [39].

In patients with brain damage, serum amylase and lipase levels can be increased (eg, cerebrovascular accident or brain trauma). These patients usually require mechanical ventilation and are treated in an intensive care unit (ICU). Elevations of pancreatic enzymes might fluctuate dramatically over days or weeks. The rise is thought to be caused by a central mechanism that causes hyperstimulation of the pancreas, yet imaging scans show no signs of acute pancreatitis. Severe acute pancreatitis necessitates immediate medical attention. A variety of problems (such as shock, lung failure, renal failure, gastrointestinal [GI] hemorrhage, or multiorgan system failure) can emerge from hours to days. Medical management's objectives are to offer active supportive care, reduce inflammation, limit infection or superinfection, and diagnose and treat consequences as needed. Autoimmune pancreatitis is a very uncommon ailment. Corticosteroids should not be used to treat this condition in the short term in patients who are suspected of having autoimmune pancreatitis and who present with acute pancreatitis [39].

There are no evidence-based standards that determine when a patient should be transferred to a medical center with higher expertise or skill. Consider transferring to an institution where an intensivist staffs the critical care unit and an interesting subspecialist experienced in the diagnosis and treatment of pancreatitis is

available if severe acute pancreatitis is suggested by the Atlanta criteria or by a C-reactive protein (CRP) level above 10 mg/dL, Ranson score of 4 or higher, or Acute Physiology and Chronic Health Evaluation (APACHE) II score of 9 or higher. Further inpatient care is contingent on whether or not serious pancreatitis complications arise and how well patients react to treatment. Intensive care might last anything from a few days to several months. When patients' pain is well controlled with oral analgesia, they can tolerate an oral diet that meets their caloric demands, and all problems have been adequately addressed, they can be discharged [40].

18. INITIAL SUPPORTIVE CARE

18.1 Fluid Resuscitation

A substantial volume of fluid is lost by patients with acute pancreatitis into the retroperitoneum and intra-abdominal regions. As a result, intravenous (IV) hydration is required during the first 24 hours. Aggressive fluid resuscitation is needed, especially in the early stages of the illness. This is something that cannot be overstated. There is no universal agreement that one type of fluid is superior to another; both crystalloids and colloids are used. To maintain hemodynamic stability, resuscitation should be sufficient. A bolus of several liters of fluid is usually given first, followed by a continuous infusion at a rate of 250-500 mL/h. As measures of appropriate hydration, central venous pressure, pulmonary artery wedge pressure, and urine output (>0.5 mL/kg/h) can be monitored. Overhydration symptoms, such as pulmonary edema causing hypoxia, should be closely monitored [40].

18.2 Nutritional Support

The following are general nutritional suggestions for patients with acute pancreatitis: There is little benefit from nutritional support in patients with mild uncomplicated pancreatitis, and the energy (caloric) intake provided by IV dextrose 5% in water (D5W) is sufficient; oral feedings should be started once the patient's discomfort and anorexia have resolved. Begin nutritional support early in the course of therapy in patients with moderate-to-severe pancreatitis, as soon as fluid and hemodynamic parameters have stabilized; ideally, nasojejunal feedings with a low-fat formulation should be started at admission. When patients cannot satisfy their caloric needs with enteral nutrition or when appropriate jejunal access cannot be maintained, total parenteral nutrition (TPN) may be required; the TPN solution should include fat emulsions insufficient levels to prevent an essential fatty acid shortage [41].

If surgery is required for diagnosis or treatment of illness problems, a feeding jejunostomy should be placed at the time of surgery and a low-fat formula should be used. Once the abdominal pain has subsided and the patient has regained an appetite, start oral feedings; the diet should be minimal in fat and protein. Theoretical concerns about the enterocyte's ability to maintain a barrier against bacterial translocation favor nasojejunal feedings, which is why all patients admitted to the intensive care unit should try to start nasojejunal feedings right away (ICU). Nasojejunal feedings should be avoided in individuals with moderate acute pancreatitis unless they are unable to tolerate oral intake for more than a week. There hasn't been any research done to see if nasojejunal tubes are better for enteral feeding than nasogastric tubes [42].

19. ANTIBIOTIC THERAPY

In any case of pancreatitis worsened by infected pancreatic necrosis, antibiotics, mainly of the imipenem class, should be given. They should not, however, be administered for fever regularly, especially early in the disease course, because this symptom is nearly always related to the inflammatory response and rarely indicates an infectious process. Several randomized controlled trials have looked into the use of empiric antibiotics for infection prevention in patients with severe acute necrotizing pancreatitis. One study looked at the effectiveness of starting imipenem-cilastatin at the time of admission to avoid infected pancreatic necrosis. The pancreatic parenchyma is penetrated by this medicine combination, which minimizes the risk of intra-abdominal infection. It appears to aid in the prevention of infectious problems. Unfortunately, fungal superinfection usually occurs later in the clinical course, albeit this risk is likely exaggerated [43].

Giving ciprofloxacin and metronidazole to prevent infection problems failed to show any effect in a randomized trial. As a result, in the case of acute pancreatitis, this medicine combination is not commonly utilized for

prophylaxis. In the end, antibiotic prophylaxis in acute pancreatitis is a contentious topic. Antibiotics should not be used routinely as a prophylactic against infection in severe acute pancreatitis at this time [43].

20. EMERGING PHARMACOLOGIC TREATMENTS

Although cytokines appear to play an essential role in the systemic inflammatory response syndrome (SIRS), a large clinical trial with lexipafant, a platelet-activating factor antagonist, found the little effect in patients with severe acute pancreatitis. Because the inflammatory response involves several pathways, more research is needed to determine which cytokine or a mix of cytokines should be targeted to alleviate acute pancreatitis symptoms. Although anti-tumor necrosis factor-alpha (TNF-) therapy has been proposed as a possible treatment for acute pancreatitis, clinical trials have yet to confirm its efficacy in this situation [44].

21. SURGICAL INTERVENTIONS

When an anatomic issue amenable to a mechanical remedy is present, surgical intervention, whether minimally invasive or traditional open procedures, is indicated (eg, acute necrotizing pancreatitis in which the necrotic phlegmon is excised to limit a potential site of sepsis or hemorrhagic pancreatitis in which surgical control of bleeding is warranted). This may necessitate the services of an interventional radiologist, an interventional endoscopist, or a surgeon, depending on the situation and local expertise (individually or in combination) [44].

22. GALLSTONE PANCREATITIS

Patients with gallstone pancreatitis should have their cholecystectomy before being discharged, rather than having it done as an outpatient procedure afterward. Patients with gallstone pancreatitis who are discharged without a cholecystectomy are at a greater risk of recurring pancreatitis. According to Aboulian et al, performing laparoscopic cholecystectomy within 48 hours of admission, regardless of whether abdominal pain or laboratory abnormalities had resolved, resulted in a shorter hospital stay and did not affect the technical difficulty of the procedure or the perioperative complication rate in patients with mild gallstone pancreatitis [45].

In a 14-year retrospective study of 316 Italian patients hospitalized for nonsevere acute gallstone pancreatitis, researchers discovered that only around a third (31%) had an early laparoscopic cholecystectomy (within 72 hours). The necessity to (1) stabilize comorbid diseases and (2) preoperatively evaluate the common bile duct were the most common reasons for the surgical delay; additional factors included considerably advanced age and an increased incidence of clinical symptoms indicating the existence of common bile duct stones. Although early laparoscopic cholecystectomy appeared to shorten overall hospitalization, clinical results were similar across individuals who had the procedure early and those who had it later [45].

Early endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy and stone extraction is indicated if imaging and laboratory findings are consistent with severe acute gallstone pancreatitis that is not responding to supportive therapy or ascending cholangitis with worsening signs and symptoms of obstruction [45].

23. PANCREATIC DUCT DISRUPTION

The pancreatic ductal system may be damaged, allowing pancreatic juice to seep out of the gland. This disorder is indicated by the onset of hypocalcemia or a fast increase in retroperitoneal fluid on computed tomography (CT). When imaging investigations confirm the diagnosis, the disease is treated by percutaneously inserting a drainage tube into the fluid accumulation while using ultrasonography or CT scanning to guide the procedure. The presence of a ductal disruption is highly suggested by fluid amylase or lipase values in the 10,000s. ERCP verifies the diagnosis and offers a therapeutic choice in the right clinical environment. By reducing the sphincter tone and modifying the dynamics of fluid flow in favor of ductal healing, a transpapillary stent or, preferably, a 6 French nasopancreatic tube linked to an external bulb suction device can successfully treat leaks. Leaks are occasionally connected with downstream stenoses that can be treated endoscopically. In some situations, refractory cases may necessitate surgery. A distal pancreatectomy is recommended if there is a chronic leak in the tail of the gland. If the leak is in the gland's head, the Whipple procedure is the best option [45].

24. PSEUDOCYSTS

Acute pseudocysts are peripancreatic fluid accumulation that lasts longer than four weeks. Pseudocysts are not real cysts since they lack an epithelial layer. They're also different from real cysts because they're frequently packed with necrotic material instead of fluid. As a result, organized necrosis may be a better term to describe pseudocysts. Clinically, most pseudocysts can be followed. Intervention is required when they are symptomatic (i.e., linked with pain, bleeding, or infection) or are greater than 7 cm and quickly expanding in a critically ill patient. Depending on the anatomic relationships and the length of the complication's natural history, a variety of treatment techniques may be used [46].

Percutaneous aspiration of pancreatic pseudocysts is a viable option in some patients with significant fluid collections. Although treatment failures are common when the pseudocyst communicates with the pancreatic ductal system, percutaneous drainage can be used as a temporary therapy before undergoing endoscopic or surgical intervention. Percutaneous drainage can often be used to treat an infected pseudocyst (which is considered a pancreatic abscess by definition). Endoscopically, pseudocysts can be treated with transpapillary or transmural methods. The primary pancreatic duct must interface with the pseudocyst cavity, ideally at the head or body of the gland, for transpapillary drainage to work. The stent's proximal end (which should be smaller than the pancreatic duct's diameter) is inserted into the cavity. The technical success rate is 83 percent, with a 12 percent complication rate. Generally, however, pancreatic stents are difficult to monitor, are prone to obstruction, and carry an increased risk of infection and ductal injury [46].

Transmural enterocystostomy may be an option for some noncommunicating pseudocysts. A developed cyst bulging into the foregut is required for technical success, and the gap between the lumen and the cyst cavity should be less than 1 cm. The success rate is 85 percent, with a 17 percent complication rate. Compared to the transgastric procedure, the transduodenal approach has fewer problems and recurrences. Surgery was suggested for chronic big (> 7 cm) pancreatic pseudocysts in the 1970s based on prospective studies that found problems in 41% of patients, with 13% of them dying. Internal pseudocyst-enteric anastomosis became the gold standard, with a 3-5 percent operative mortality rate. This assumption was later debunked by two retrospective investigations that found that individuals with smaller (i.e., less than 5 cm) asymptomatic pseudocysts only infrequently (less than 10%) suffered problems [46].

25. INFECTED PANCREATIC NECROSIS

To distinguish between infected and sterile pancreatic necrosis, the clinician cannot depend solely on clinical signs. CT-guided needle aspiration is indicated when clinical symptoms of infection or SIRS are present in the setting of necrotizing pancreatitis. When substantial parts of the pancreas are necrotic and percutaneous CT-guided aspiration reveals infection due to a positive Gram stain, surgery is advised. Antibiotic medication isn't enough to get rid of the infection. To remove dead tissue and eliminate the infection, aggressive surgical debridement and drainage are required. In a trial of individuals with necrotizing pancreatitis and infected necrotic tissue, a step-up strategy to treatment (percutaneous drainage followed, if necessary, by minimally invasive retroperitoneal necrosectomy) outperformed standard care with open necrosectomy. Major problems (new-onset multiorgan failure, numerous systemic issues, perforation of a visceral organ, enterocutaneous fistula, or hemorrhage) and death were less common in patients who received step-up treatment [47].

26. PANCREATIC ABSCESS

Pancreatic abscesses are most common in the later stages of pancreatitis. Many of them respond to antibiotics and percutaneous catheter drainage. Surgical debridement and drainage are required for those who do not respond [47].

27. PROGNOSIS

Acute pancreatitis has a 1 to 2% overall fatality rate; however, severe acute pancreatitis has a substantially higher yet unclear mortality rate. To define the level of care, a severity assessment and prognostication are critical. There have been several clinical prediction measures developed and validated. The majority of them are time-consuming to calculate and require 48-hour data. The BISAP (Bedside Index for Severity in Acute Pancreatitis) is a newer addition to this list. This index has been prospectively tested and is

simple and quick to calculate from initial presentation data. It has strong predictive performance for both severe acute pancreatitis and death. The CT Severity Index (CTSI) can also help predict mortality, with the presence of any necrosis on CT imaging indicating a high risk of death [47].

28. DISCUSSION

This article discusses how to recognize acute pancreatitis and how to treat it. Pancreatitis is an inflammatory condition in which pancreatic enzymes break down the pancreatic tissue on their own. Acute pancreatitis is a condition in which the pancreas recovers without causing any functional or morphologic alterations. Pancreatitis can also reoccur regularly, leading to the gland's functional and morphologic deterioration; this is referred to as chronic pancreatitis. Both types of pancreatitis might appear with acute clinical symptoms in the emergency department (ED). It is crucial to recognize patients with severe acute pancreatitis as soon as possible to achieve the best potential results [48].

Laboratory tests are conducted to support the clinical impression, to assist identify the etiology, and to search for complications after a working diagnosis of acute pancreatitis is reached. In most situations, diagnostic imaging is unnecessary, although it may be done if the diagnosis is in doubt, if acute pancreatitis is present, or if an imaging study could provide particular information to answer a clinical question. The use of image-guided aspiration may be beneficial. It's possible that genetic testing will be considered. The severity of the problem has a big impact on how it's handled. Mild acute pancreatitis has a relatively simple medical treatment. The goal of medical management for severe acute pancreatitis is to give vigorous supportive care, reduce inflammation, limit infection or superinfection, and diagnose and treat consequences as needed. In some circumstances, surgical intervention (open or minimally invasive) is required [48].

The pathophysiology of acute pancreatitis is based on the premature activation of the zymogen trypsinogen, which causes local pancreatic destruction and activation of the inflammatory cascade, resulting in the systemic inflammatory response syndrome (SIRS), which is frequently associated with acute pancreatitis. Multiorgan dysfunction syndrome can be caused by systemic inflammation (MODS). The Revised Atlanta Criteria states that acute pancreatitis must meet at least two of the following three criteria: 1) lipase or amylase levels three times the upper limit of normal, 2) physical exam consistent with pancreatitis, and 3) imaging (CT, MRI, ultrasound) findings consistent with acute pancreatitis. The BISAP (Bedside Index Severity in Acute Pancreatitis) score can be used to help triage patients for the appropriate degree of care. This index has good predictive performance for both severe acute pancreatitis and mortality and has been validated prospectively, is simple and easy to calculate from initial presentation data [48].

The first 12 to 24 hours after admission are crucial in the treatment of acute pancreatitis. Appropriate fluid resuscitation can dramatically reduce complications and mortality during this time. To provide appropriate fluid resuscitation, close monitoring of vital signs and basic labs is essential. Idiopathic pancreatitis still accounts for 10 to 20% of acute pancreatitis patients, posing a diagnostic and treatment challenge. Recent research has focused on the appropriate use of EUS and ERCP in these situations, with a more cautious approach to ERCP due to its relatively high rate of triggering post-procedural pancreatitis [48].

29. CONCLUSION

Inflammation of the pancreas (pancreatitis) can take many forms in children and adolescents, ranging from intrauterine congenital onset with the consequences of early exocrine pancreatic insufficiency, as in cystic fibrosis and Shwachman-Diamond syndrome, to postnatal onset as a result of embryologic anomalies affecting pancreatic drainage, postulated to exist in the pancreas divisum, or traumatic, o The cause is frequently unknown, with up to 30% of cases being idiopathic. Endoscopic ultrasonography and magnetic resonance cholangiopancreatography are modern imaging modalities that extend the diagnostic capability of traditional abdominal ultrasonography and computed tomography. In addition, the pediatric endoscopic retrograde cholangiopancreatography experience is growing. In situations of pancreatic necrosis and pseudocyst, medical care remains supportive, with optimal timing and indications for surgery being explored. Acute pancreatitis, recurring acute pancreatitis, and chronic pancreatitis are the three types of pancreatitis seen in children.

Acute pancreatitis is characterized by quick onset, generally due to a specific reason, and a range of severity and length, but it is self-limited and eventually resolves. Acute recurrent pancreatitis is defined by acute pancreatitis attacks that occur after periods of remission and reflect an underlying problem or predisposition. Most of these instances have chronic pancreatitis, which means that the inflammation and damage of the pancreas never go away completely.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Abu-El-Haija M, Kumar S, Quiros JA, Balakrishnan K, Barth B, Bitton S, Eisses JF, Foglio EJ, Fox V, Francis D, Freeman AJ, Gonska T, Grover AS, Husain SZ, Kumar R, Lapsia S, Lin T, Liu QY, Maqbool A, Sellers ZM, Szabo F, Uc A, Werlin SL, Morinville VD. Management of acute pancreatitis in the pediatric population: A clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pancreas Committee. J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):159-176.
2. Akhtar AJ, Shaheen M. Extrapancreatic manifestations of acute pancreatitis in African-American and Hispanic patients. Pancreas. 2004 Nov. 29(4):291-7.
3. Amas Gómez L, Zubia Olaskoaga F. Results of the modification of an acute pancreatitis management protocol in Intensive Care medicine. Med Intensiva (Engl Ed). 2019 Dec;43(9):546-555.
4. Arvanitakis M, Dumonceau JM, Albert J, Badaoui A, Bali MA, Barthet M, Besselink M, Deviere J, Oliveira Ferreira A, Gyökeres T, Hritz I, Hucl T, Milashka M, Papanikolaou IS, Poley JW, Seewald S, Vanbiervliet G, van Lienden K, van Santvoort H, Voermans R, Delhaye M, van Hooft J. Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary guidelines. Endoscopy. 2018 May;50(5):524-546.
5. Bakker OJ, van Brunschot S, van Santvoort HC, et al, for the Dutch Pancreatitis Study Group. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. N Engl J Med. 2014 Nov 20;371(21):1983-93.
6. Banks PA, Bollen TL, Dervenis C, et al, for the Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11.
7. Barbara M, Tsen A, Rosenkranz L. Acute Pancreatitis in Chronic Dialysis Patients. Pancreas. 2018 Sep;47(8):946-951.
8. Barrie J, Jamdar S, Smith N, McPherson SJ, Siriwardena AK, O'Reilly DA. Mis-use of antibiotics in acute pancreatitis: Insights from the United Kingdom's National Confidential Enquiry into patient outcome and death (NCEPOD) survey of acute pancreatitis. Pancreatology. 2018 Oct;18(7):721-726.
9. Bazerbachi F, Haffar S, Hussain MT, Vargas EJ, Watt KD, Murad MH, Chari S, Abu Dayyeh BK. Systematic review of acute pancreatitis associated with interferon-α or pegylated interferon-α: Possible or definitive causation? Pancreatology. 2018 Oct;18(7):691-699.
10. Branquinho D, Ramos-Andrade D, Elvas L, Amaro P, Ferreira M, Sofia C. Drug-induced acute pancreatitis and pseudoaneurysms: An ominous combination. GE Port J Gastroenterol. 2016 Nov-Dec;23(6):309-313.
11. Choi HW, Park HJ, Choi SY, Do JH, Yoon NY, Ko A, Lee ES. Early prediction of the severity of acute pancreatitis using radiologic and clinical scoring systems with classification tree analysis. AJR Am J Roentgenol. 2018 Nov;211(5):1035-1043.
12. Constantinoiu S, Cochior D. Severe acute pancreatitis - determinant factors and current therapeutic conduct. Chirurgia (Bucur). 2018 May-Jun;113(3):385-390.
13. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN, American Gastroenterological association institute clinical guidelines committee. american gastroenterological association institute guideline on initial management of acute pancreatitis. Gastroenterology. 2018 Mar.; 154(4):1096-101.
14. de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical

management. United European Gastroenterol J. 2018 Jun;6(5):649-655.
15. Duzenci D, Yalnız M, Ispiroglu M. Comparison between prognostic indicators in organ insufficiency with acute pancreatitis. Ulus Travma Acil Cerrahi Derg. 2021 Jul. 27(4):410-20.
16. Fonseca Sepúlveda EV, Guerrero-Lozano R. Acute pancreatitis and recurrent acute pancreatitis: an exploration of clinical and etiologic factors and outcomes. J Pediatr (Rio J). 2019 Nov - Dec;95(6): 713-719.
17. Garret C, Péron M, Reignier J, Le Thuaut A, Lascarrou JB, Douane F, Lerhun M, Archambeaud I, Brulé N, Bretonnière C, Zambon O, Nicolet L, Regenet N, Guitton C, Coron E. Risk factors and outcomes of infected pancreatic necrosis: Retrospective cohort of 148 patients admitted to the ICU for acute pancreatitis. United European Gastroenterol J. 2018 Jul;6(6):910-918.
18. Gódi S, Erőss B, Gyömbér Z, Szentesi A, Farkas N, Párniczky A, Sarlós P, Bajor J, Czimmer J, Mikó A, Márta K, Hágendorn R, Márton Z, Verzár Z, Czakó L, Szepes Z, Vincze Á, Hegyi P. Centralized care for acute pancreatitis significantly improves outcomes. J Gastrointestin Liver Dis. 2018 Jun;27(2):151-157.
19. Guadagni S, Cengeli I, Palmeri M, et al. Early cholecystectomy for non-severe acute gallstone pancreatitis: easier said than done. Minerva Chir. 2017 Apr. 72(2):91-7.
20. Huh JH, Jeon H, Park SM, et al. Diabetes mellitus is associated with mortality in acute pancreatitis. J Clin Gastroenterol. 2018 Feb. 52(2):178-83.
21. Jacobson BC, Vander Vliet MB, Hughes MD, Maurer R, McManus K, Banks PA. A prospective, randomized trial of clear liquids versus low-fat solid diet as the initial meal in mild acute pancreatitis. Clin Gastroenterol Hepatol. 2007 Aug. 5(8):946-51.
22. Jin T, Jiang K, Deng L, Guo J, Wu Y, Wang Z, Shi N, Zhang X, Lin Z, Asrani V, Jones P, Mittal A, Phillips A, Sutton R, Huang W, Yang X, Xia Q, Windsor JA. Response and outcome from fluid resuscitation in acute pancreatitis: a prospective cohort study. HPB (Oxford). 2018 Nov;20(11):1082-1091.
23. Kahaleh M. Management of pancreatitis and pancreatic: fluid collections. Rev Gastroenterol Peru. 2018 Apr-Jun;38(2):169-182.
24. Khan A, Sarma D, Gowda C, Rodrigues G. The role of Modified Early Warning Score (MEWS) in the prognosis of acute pancreatitis. Oman Med J. 2021 May. 36(3):e272.
25. Kim SB, Kim TN, Chung HH, Kim KH. Small gallstone size and delayed cholecystectomy increase the risk of recurrent pancreatobiliary complications after resolved acute biliary pancreatitis. Dig Dis Sci. 2017 Mar.;62(3):777-83.
26. Kirkegård J, Cronin-Fenton D, Heide-Jørgensen U, Mortensen FV. Acute pancreatitis and pancreatic cancer risk: A nationwide matched-cohort study in Denmark. Gastroenterology. 2018 May; 154(6):1729-1736.
27. Kothari S, Kalinowski M, Kobeszko M, Almouradi T. Computed tomography scan imaging in diagnosing acute uncomplicated pancreatitis: Usefulness vs cost. World J Gastroenterol. 2019 Mar 7;25(9):1080-7.
28. Krishna SG, Kamboj AK, Hart PA, Hinton A, Conwell DL. The changing epidemiology of acute pancreatitis hospitalizations: a decade of trends and the impact of chronic pancreatitis. Pancreas. 2017 Apr.;46(4):482-8.
29. Krishnan K. Nutritional management of acute pancreatitis. Curr Opin Gastroenterol. 2017 Mar. ;33(2):102-6.
30. Li H, Qian Z, Liu Z, Liu X, Han X, Kang H. Risk factors and outcome of acute renal failure in patients with severe acute pancreatitis. J Crit Care. 2010 Jun. 25(2):225-9.
31. Machicado JD, Yadav D. Epidemiology of recurrent acute and chronic pancreatitis: similarities and differences. Dig Dis Sci. 2017 Jul. 62(7):1683-91.
32. Mikolasevic I, Orlic L, Poropat G, et al. Nonalcoholic fatty liver and the severity of acute pancreatitis. Eur J Intern Med. 2017 Mar.;38:73-8.
33. Parihar V, Ridgway PF, Conlon KC, Huggett M, Ryan BM. The role of endoscopic intervention in the management of inflammatory pancreatic fluid collections. Eur J Gastroenterol Hepatol. 2017 Apr. 29(4):371-9.
34. Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019 Jan. 156(1):254-72.e11.

35. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012 Nov.;143(5):1179-1187.e3.
36. Petrov MS, Yadav D. Global epidemiology and holistic prevention of pancreatitis. Nat Rev Gastroenterol Hepatol. 2019 Mar. 16(3):175-84.
37. Reynolds PT, Brady EK, Chawla S. The utility of early cross-sectional imaging to evaluate suspected acute mild pancreatitis. Ann Gastroenterol. 2018 Sep-Oct;31(5):628-632.
38. Sellers ZM, Abu-El-Haija M, Husain SZ, Morinville V. New Management Guidelines for Both Children and Adults With Acute Pancreatitis. Gastroenterology. 2018 Jul;155(1):234-235.
39. Smeets XJNM, Litjens G, Gijsbers K, Prokop M, Drenth JPH, Hermans J, van Geenen EJM. The accuracy of pancreatic perfusion computed tomography and angiography in predicting necrotizing pancreatitis: A systematic review. Pancreas. 2018 Jul;47(6):667-674.
40. Srinivasan G, Venkatakrishnan L, Sambandam S, Singh G, Kaur M, Janarthan K, John BJ. Current concepts in the management of acute pancreatitis. J Family Med Prim Care. 2016 Oct-Dec;5(4):752-758.
41. Suppiah A, Malde D, Arab T, et al. The prognostic value of the neutrophil-lymphocyte ratio (NLR) in acute pancreatitis: identification of an optimal NLR. J Gastrointest Surg. 2013 Apr. ;17(4):675-81.
42. Tenner S, Baillie J, DeWitt J, Vege SS, and the American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep.;108(9):1400-15; 1416.
43. Testoni PA, Mariani A, Giussani A, et al, for the SEIFRED Group. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol. 2010 Aug.;105(8):1753-61.
44. Valverde-López F, Wilcox CM, Redondo-Cerezo E. Evaluation and management of acute pancreatitis in Spain. Gastroenterol Hepatol. 2018 Dec;41(10):618-628.
45. van Santvoort HC, Besselink MG, Bakker OJ, et al, for the Dutch Pancreatitis Study Group. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010 Apr 22. 362(16):1491-502.
46. Vege SS, DiMagno MJ, Forsmark CE, Martel M, Barkun AN. Initial medical treatment of acute pancreatitis: American Gastroenterological Association Institute Technical Review. Gastroenterology. 2018 Mar.;154(4):1103-39.
47. Vege SS, Ziring B, Jain R, Moayyedi P, and the Clinical Guidelines Committee, American Gastroenterology Association. American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015 Apr. 148(4):819-22.
48. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013 Jun.;144(6):1252-61.